KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.

Name: KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Author: Nishio, Makoto

KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. — المؤلف: Nishio, Makoto — Cancer science 20190308

المؤلف: Nishio, Makoto
النشر: Cancer science 20190308
الوصف: 1012-1020 p.
الموضوعات: Aged؛ Antibodies, Monoclonal, Humanized؛ Antineoplastic Agents؛ Asian People؛ B7-H1 Antigen؛ Carcinoma, Non-Small-Cell Lung؛ Disease-Free Survival؛ Female